SKBI News Alert Skystar Bio-Pharmaceutical Company (SKBI) 4.22

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 12:38 PM

Skystar Bio-Pharmaceutical Company (SKBI) 4.22 $SKBI

InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI
InsiderInsights - at Seeking Alpha - Tue Dec 30, 12:23PM CST

GD: 137.61 (-0.54), SKBI: 4.22 (+0.03), PTBI: 3.10 (unch), FMD: 5.45 (-0.16), GHC: 976.65 (+15.51), VRML: 2.08 (+0.12), ADBE: 76.51 (+1.92), OHAI: 4.67 (+0.01), KERX: 11.63 (-0.60), BH: 416.41 (-1.55), LII: 104.27 (+0.88), JAZZ: 169.69 (+6.89), NMBL: 23.19 (+0.81), REGN: 402.40 (+0.66), OAS: 16.84 (-0.03), XLRN: 38.02 (+0.07), SYK: 94.51 (+1.14), CRM: 62.85 (+1.59)

Update: Skystar Bio-Pharmaceutical Company Q3 Earnings - Key Developments
David Zanoni - at Seeking Alpha - Wed Nov 19, 2:00AM CST

SKBI: 4.22 (+0.03)

Skystar Bio-Pharmaceutical Company (SKBI) Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 17, 6:48PM CST

SKBI: 4.22 (+0.03)

Skystar Bio reports Q3 profit
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 4:20PM CST

SKBI: 4.22 (+0.03)

Skystar Bio-Pharmaceutical Reports Third Quarter Fiscal Year 2014 Financial Results
Marketwired - Fri Nov 14, 4:01PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"

, a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today reported unaudited third quarter fiscal year 2014 earnings, for the period ended September 30, 2014.
SKBI: 4.22 (+0.03)

Skystar Bio-Pharmaceutical to File Financial Results for Third Quarter of Fiscal 2014 on Friday, November 14
Marketwired - Fri Nov 14, 12:00PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"

, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the third quarter of fiscal 2014 on Friday, November 14, 2014 by close of the business day.
SKBI: 4.22 (+0.03)

Skystar Bio-Pharma Featured on Wide World of Stocks Television
Marketwired - Wed Nov 05, 1:33PM CST
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced that the interview of Mr. Scott Cramer, Director, Corporate Development and U.S. Representative for Skystar, on Wide World of Stocks will broadcast today, Wednesday, November 5, 2014 into more than 50 million homes nationwide over BizTV, BizTV Radio, and You Tube America Networks.
SKBI: 4.22 (+0.03)

Market Maker Surveillance Report. BDR, HDY, LUNA, EFOI, SKBI, KUTV, Losing Stocks With Lowest Price Friction For Friday, September 12th 2014
M2 - Mon Sep 15, 2:54AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 4813 companies with "abnormal" market making, 1557 companies with positive Friction Factors and 3492 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage loss per share Friday and low price friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. Blonder Tongue Laboratories Inc (NYSE:BDR), Hyperdynamics Corp (NYSE:HDY), Luna Innovations Inc (NASDAQ:LUNA), Energy Focus Inc (NASDAQ:EFOI), Skystar Bio Pharmaceutical Co (NASDAQ:SKBI), Ku6 Media Co Ltd (NASDAQ:KUTV). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
SKBI: 4.22 (+0.03), LUNA: 1.48 (-0.01), EFOI: 4.60 (+0.44), BDR: 1.71 (-0.02), KUTV: 1.00 (+0.01), HDY: 0.90 (unch)

3 Stocks Under $10 Moving Higher
at The Street - Wed Sep 10, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
SKBI: 4.22 (+0.03), REPH: 3.13 (-0.12)

Skystar Bio-Pharmaceutical (SKBI) Upgraded From Hold to Buy
at The Street - Tue Sep 09, 8:21AM CDT
Skystar Bio-Pharmaceutical (SKBI) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
SKBI: 4.22 (+0.03)

Skystar to Launch Probiotic Supplement for Dairy Cows by End of Fiscal 2014
Marketwire - Tue Aug 26, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, announced preparations to launch a new probiotic product for dairy cows by the end of fiscal 2014. The dairy cow probiotic is developed for the milk production industry in China and is designed to introduce Bacillus Subtilis (B. subtilis), also known as "Hay Bacillus," into the digestive tract of milk producing cows. Hay Bacillus has been proven to aid in the digestion and breakdown of hay in the animals' rumen canal.
SKBI: 4.22 (+0.03)

Skystar Bio-Pharmaceutical Reports Second Quarter Fiscal Year 2014 Financial Results
Marketwire - Thu Aug 14, 5:59PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"

, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, today reported unaudited second quarter fiscal year 2014 earnings, for the period ended June 30, 2014.
SKBI: 4.22 (+0.03)

Skystar Bio-Pharmaceutical to File Financial Results for Second Quarter of Fiscal 2014 on Thursday, August 14
Marketwire - Thu Aug 14, 5:31PM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) ("Skystar" or the "Company"

, a China-based manufacturer and distributor of veterinary medicines, vaccines, micro-organisms and feed additives, will file its financial results for the second quarter of fiscal 2014 on Thursday, August 14, 2014 by close of the business day.
SKBI: 4.22 (+0.03)

Skystar Bio-Pharmaceutical Announces $5 Million Registered Direct Offering
Marketwire - Wed Jul 16, 7:59AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announces that it has entered into a definitive agreement with a dedicated healthcare institutional investor to purchase an aggregate of $5,000,000 of registered securities of the Company in a registered direct offering. Pursuant to the terms of the agreement, the investor shall purchase from the Company 790,514 shares of common stock and warrants to purchase up to 197,629 shares of common stock for an aggregate purchase price of $4,000,000 and 1,000 shares of convertible preferred stock and warrants to purchase up to 49,407 shares of common stock for an aggregate purchase price of $1,000,000.
SKBI: 4.22 (+0.03)

Skystar unveils new bovine IgG kits in China for domestic pig farming communities
M2 - Wed Jul 09, 6:32AM CDT
Veterinary company Skystar Bio-Pharmaceutical Company (NASDAQ:SKBI) reported on Tuesday the availability of its new product in China, called bovine immunoglobulin G (IgG) kits, targeting China's domestic pig farming communities.
SKBI: 4.22 (+0.03)

Skystar Launches Bovine Immunoglobulin G (IgG) Kits in China
Marketwire - Tue Jul 08, 8:04AM CDT
Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI), a China-based manufacturer and distributor of veterinary medicine, vaccines, micro-organisms and feed additives, today announced the launch of a new product in China -- bovine immunoglobulin G (IgG) kits targeting China's domestic pig farming communities. This product helps to prevent and treat blue ear disease, respiratory pneumonia, pseudorabies, swine fever and foot and mouth disease which are common diseases affecting pig in the farming industry.
SKBI: 4.22 (+0.03)

23.3% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Mon Jul 07, 11:08AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 23.26% as of today's recent price of $7.79.
SKBI: 4.22 (+0.03)

12.7% Return Seen to Date on SmarTrend Skystar Bio-Pharmaceutical Call (SKBI)
Comtex SmarTrend(R) - Fri Jun 27, 9:26AM CDT
SmarTrend identified an Uptrend for Skystar Bio-Pharmaceutical (NASDAQ:SKBI) on April 24th, 2014 at $6.32. In approximately 2 months, Skystar Bio-Pharmaceutical has returned 12.66% as of today's recent price of $7.12.
SKBI: 4.22 (+0.03)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Vayo Debuts as Booking Holdings Eyes $100M Investment

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

FCS Drives Key FDA Approvals in Cancer Treatment

Florida Cancer Specialists: Changing the Cancer Treatment Game Some organizations toot their horns, but every now and then, a group truly shakes up the playing field. Take Florida Cancer Specialists & Research Institute (FCS), for instance. Over years of relentless research, FCS has nailed its role in securing two significant FDA approvals aimed at expanding treatment...

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

Honeywell Aerospace Faces Legal Turbulence in Fraud Case

If you've got your chips on Honeywell Aerospace, Inc. (HONA), buckle up because things are getting choppy. Investors who took a bath on their shares now have the chance to put on their legal gloves and join a securities fraud class action lawsuit against the company. Legal Storm Over Misleading Statements Here's the rub: Between June 29 and September 1, 2026, the folks at...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...